Literature DB >> 1385427

Angiotensin II regulates tenascin gene expression in vascular smooth muscle cells.

B G Sharifi1, D W LaFleur, C J Pirola, J S Forrester, J A Fagin.   

Abstract

Angiotensin II, a vasoactive peptide, has been implicated in the pathophysiology of a number of vascular wall abnormalities. Since aberrant extracellular matrix deposition contributes to the pathogenesis of vessel wall disease, we examined the potential involvement of angiotensin II in the regulation of extracellular matrix synthesis by vascular smooth muscle cells. Immunoprecipitation of newly synthesized matrix proteins showed that, under serum-free conditions, cultured vascular smooth muscle cells constitutively produced high levels of fibronectin, small amounts of laminin, and a barely detectable amount of tenascin. Angiotensin II treatment increased synthesis of a 230-kDa tenascin glycoprotein by 9-fold and fibronectin synthesis by only 30-40% during a 24-h treatment period, without stimulating laminin production or a general increase in the synthesis of secreted proteins. Concomitant treatment with saralasin, a competitive inhibitor of angiotensin II, prevented the stimulation observed with angiotensin II. The stimulation of immunoprecipitable tenascin was preceded by an increase in tenascin mRNA. Levels of tenascin transcripts (8.4 and 7.0 kilobase) were significantly increased within 2 h after angiotensin II treatment, reached a maximum (10- to 12-fold) by 4 h, and remained elevated after 18 h. The induction was completely blocked by actinomycin D. Serum also induced tenascin mRNA, but with a different time course. Serum induction of tenascin mRNA was also evident at 2 h, maximal at 4 h, but declined to control levels at 8 h. These results indicate that angiotensin II exerts a rapid and selective stimulation of tenascin biosynthesis, at least in part at a transcriptional level. This suggests that angiotensin II may alter the composition of the extracellular matrix of the vessel wall by stimulating synthesis of the antiadhesive protein tenascin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385427

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Deletion of tenascin-C gene exacerbates atherosclerosis and induces intraplaque hemorrhage in Apo-E-deficient mice.

Authors:  Lai Wang; Wei Wang; Prediman K Shah; Lei Song; Mingjie Yang; Behrooz G Sharifi
Journal:  Cardiovasc Pathol       Date:  2012-02-01       Impact factor: 2.185

2.  Tenascin-C deficiency in apo E-/- mouse increases eotaxin levels: implications for atherosclerosis.

Authors:  Lai Wang; Prediman K Shah; Wei Wang; Lei Song; Mingjie Yang; Behrooz G Sharifi
Journal:  Atherosclerosis       Date:  2013-02-11       Impact factor: 5.162

3.  A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics.

Authors:  Fernando García-Marqués; Marco Trevisan-Herraz; Sara Martínez-Martínez; Emilio Camafeita; Inmaculada Jorge; Juan Antonio Lopez; Nerea Méndez-Barbero; Simón Méndez-Ferrer; Miguel Angel Del Pozo; Borja Ibáñez; Vicente Andrés; Francisco Sánchez-Madrid; Juan Miguel Redondo; Elena Bonzon-Kulichenko; Jesús Vázquez
Journal:  Mol Cell Proteomics       Date:  2016-02-18       Impact factor: 5.911

4.  Differential expression of tenascin in the skin during hapten-induced dermatitis.

Authors:  Y Koyama; K Norose; M Kusubata; S Irie; M Kusakabe
Journal:  Histochem Cell Biol       Date:  1996-09       Impact factor: 4.304

5.  Stimulation of activin A expression in rat aortic smooth muscle cells by thrombin and angiotensin II correlates with neointimal formation in vivo.

Authors:  J E Pawlowski; D S Taylor; M Valentine; M E Hail; P Ferrer; M C Kowala; C J Molloy
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

6.  Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. No relation between the polymorphism and aortic collagen content.

Authors:  L M Rasmussen; T Ledet
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

7.  The c-Jun-induced transformation process involves complex regulation of tenascin-C expression.

Authors:  A Mettouchi; F Cabon; N Montreau; V Dejong; P Vernier; R Gherzi; G Mercier; B Binétruy
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

8.  Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease.

Authors:  Mollie A Minear; David R Crosslin; Beth S Sutton; Jessica J Connelly; Sarah C Nelson; Shera Gadson-Watson; Tianyuan Wang; David Seo; Jeffrey M Vance; Michael H Sketch; Carol Haynes; Pascal J Goldschmidt-Clermont; Svati H Shah; William E Kraus; Elizabeth R Hauser; Simon G Gregory
Journal:  Hum Genet       Date:  2011-02-05       Impact factor: 4.132

9.  Tenascin-C, proliferation and subendothelial fibronectin in progressive pulmonary vascular disease.

Authors:  P L Jones; K N Cowan; M Rabinovitch
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

10.  Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits.

Authors:  Amit K Mitra; Guanghong Jia; Deepak M Gangahar; Devendra K Agrawal
Journal:  J Cell Mol Med       Date:  2008-03-19       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.